Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
Citi
Cantor Fitzgerald
Fuji
Chubb
Medtronic
Moodys
Harvard Business School
UBS

Generated: November 18, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021710

« Back to Dashboard

NDA 021710 describes EQUETRO, which is a drug marketed by Validus Pharms and is included in one NDA. It is available from one supplier. There is one patent protecting this drug and two Paragraph IV challenges. Additional details are available on the EQUETRO profile page.

The generic ingredient in EQUETRO is carbamazepine. There are twenty-seven drug master file entries for this compound. Thirty-nine suppliers are listed for this compound. Additional details are available on the carbamazepine profile page.
Summary for 021710
Tradename:EQUETRO
Applicant:Validus Pharms
Ingredient:carbamazepine
Patents:1
Formulation / Manufacturing:see details
Suppliers and Packaging for NDA: 021710
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
EQUETRO carbamazepine CAPSULE, EXTENDED RELEASE;ORAL 021710 NDA Validus Pharmaceuticals LLC 30698-419 30698-419-12 120 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (30698-419-12)
EQUETRO carbamazepine CAPSULE, EXTENDED RELEASE;ORAL 021710 NDA Validus Pharmaceuticals LLC 30698-421 30698-421-12 120 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (30698-421-12)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:CAPSULE, EXTENDED RELEASE;ORALStrength100MG
Approval Date:Dec 10, 2004TE:RLD:Yes
Patent:➤ Sign UpPatent Expiration:May 19, 2024Product Flag?Substance Flag?Delist Request?
Patented Use:THE RECOMMENDED INITIAL DOSE OF EQUETRO IS 400MG/DAY GIVEN IN DIVIDED DOSES, TWICE DAILY. THE DOSE SHOULD BE ADJUSTED IN 200MG DAILY INCREMENTS TO ACHIEVE OPTIMAL CLINICAL RESPONSE.

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:CAPSULE, EXTENDED RELEASE;ORALStrength200MG
Approval Date:Dec 10, 2004TE:RLD:Yes
Patent:➤ Sign UpPatent Expiration:May 19, 2024Product Flag?Substance Flag?Delist Request?
Patented Use:THE RECOMMENDED INITIAL DOSE OF EQUETRO IS 400MG/DAY GIVEN IN DIVIDED DOSES, TWICE DAILY. THE DOSE SHOULD BE ADJUSTED IN 200MG DAILY INCREMENTS TO ACHIEVE OPTIMAL CLINICAL RESPONSE.

Profile for product number 003

Active Rx/OTC/Discontinued:RXDosage:CAPSULE, EXTENDED RELEASE;ORALStrength300MG
Approval Date:Dec 10, 2004TE:RLD:Yes
Patent:➤ Sign UpPatent Expiration:May 19, 2024Product Flag?Substance Flag?Delist Request?
Patented Use:THE RECOMMENDED INITIAL DOSE OF EQUETRO IS 400MG/DAY GIVEN IN DIVIDED DOSES, TWICE DAILY. THE DOSE SHOULD BE ADJUSTED IN 200MG DAILY INCREMENTS TO ACHIEVE OPTIMAL CLINICAL RESPONSE.

Expired US Patents for NDA 021710

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Validus Pharms EQUETRO carbamazepine CAPSULE, EXTENDED RELEASE;ORAL 021710-001 Dec 10, 2004 ➤ Sign Up ➤ Sign Up
Validus Pharms EQUETRO carbamazepine CAPSULE, EXTENDED RELEASE;ORAL 021710-002 Dec 10, 2004 ➤ Sign Up ➤ Sign Up
Validus Pharms EQUETRO carbamazepine CAPSULE, EXTENDED RELEASE;ORAL 021710-003 Dec 10, 2004 ➤ Sign Up ➤ Sign Up
Validus Pharms EQUETRO carbamazepine CAPSULE, EXTENDED RELEASE;ORAL 021710-002 Dec 10, 2004 ➤ Sign Up ➤ Sign Up
Validus Pharms EQUETRO carbamazepine CAPSULE, EXTENDED RELEASE;ORAL 021710-001 Dec 10, 2004 ➤ Sign Up ➤ Sign Up
Validus Pharms EQUETRO carbamazepine CAPSULE, EXTENDED RELEASE;ORAL 021710-003 Dec 10, 2004 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fish and Richardson
US Department of Justice
Dow
Chubb
US Army
Covington
Teva
Federal Trade Commission
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.